The February 20 Supreme Court ruling invalidated the International Emergency Economic Powers Act (IEEPA) as a legal basis for general customs duties, forcing compliance systems to track three simultaneous tariff scenarios for $35.5 billion in annual Swiss pharmaceutical imports: the current 10% interim rate, the 15% framework ceiling, and a potential 39% reversion.

Washington responded to the ruling by introducing new across-the-board tariffs of 10% under a separate legal framework, valid for only 150 days. This creates a hard deadline for compliance engineering teams managing Swiss HTS classifications—any rate caching logic must account for provisional status and potential mid-year changes.

Key Rate Timeline: August 2025 saw 39% tariffs on Swiss imports. November 2025 framework deal reduced rates to 15%. February 20, 2026 Supreme Court ruling triggered 10% interim duties under new authority. The 150-day validity window expires approximately mid-July 2026.

The November framework deal had capped Section 232 pharmaceutical duties at 15%, a critical ceiling given the administration had floated rates as high as 100% on certain patented drugs. Roche, Novartis, and Sandoz supply chains depend on this cap holding. However, Swiss President Guy Parmelin confirmed that the Supreme Court decision "has cast doubt on part of the legal basis used by the United States," leaving the 15% cap legally provisional.

System Alert: Compliance platforms pulling Swiss pharmaceutical rates must implement logic for three distinct scenarios: (1) current 10% interim rate under new framework, (2) 15% rate if framework deal is finalized, (3) 39% rate if talks collapse and original tariffs are reimposed. Hard-coded rates will fail validation.

The March deadline for finalizing the Swiss agreement passed without resolution. Parmelin stated negotiations will continue into Q2 2026, with an April session expected as the next critical juncture. For HTS data consumers, this means Swiss pharmaceutical and medical device classifications remain in flux through at least mid-year.

The scope extends beyond pharmaceuticals. Precision instruments, luxury watches, medical devices, and specialty foods—sectors representing Switzerland's $38.3 billion goods surplus with the U.S. in 2024—all face the same rate uncertainty. Reciprocal concessions covering U.S. agricultural exports (nuts, seafood, fruits, spirits) to Switzerland and Liechtenstein are similarly unsigned.

Compliance systems serving importers of Swiss goods should implement rate versioning that tracks the legal authority underlying each duty rate, not just the rate percentage. The IEEPA invalidation demonstrates that statutory basis matters for rate durability—a 15% rate under IEEPA authority has different persistence characteristics than a 15% rate under Section 232 or a new congressional framework.

TradeFacts.io tracks these changes nightly. Start a free 30-day trial.